Loading…
← CockpitCompetitor Analysis › 002001.SZ Zhejiang NHU Co. Ltd. Class AOpen in the cockpit ↗

Zhejiang NHU Co. Ltd. Class A002001.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

World's largest vitamin producer, making vitamins, nutrition additives, fragrances and specialty chemicals.

≈ China's DSM-Firmenich for vitamins/nutritionMomentum strong 72
Mkt cap
$11.8B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$81.4M
20-day average traded
Fwd P/E
9.7×
forward earnings
ROIC−WACC
+16.8 pp
WACC 6.2%
Hurdle
-25 pp
Req g minus delivered
Next earnings
155 days
22 Apr 2027
Close · CNYCN¥25.82
1D-0.9%
1W-0.3%
1M-1.8%
3M-8.6%
6M-21.6%
YTD+2.5%
1Y+6.5%
ATR %2.5%
52w lowhigh35.8% off high

What Zhejiang NHU does

World's largest vitamin producer, making vitamins, nutrition additives, fragrances and specialty chemicals.

Sells vitamins and feed additives as commodity chemicals, so earnings follow the price of vitamins A and E, set among a few global producers, and its cost edge. Methionine, an amino acid fed to livestock, is a newer large line. The Hu family founded and controls it.

In one line: China's DSM-Firmenich for vitamins/nutrition.

Products and services

  • Vitamins (A, E, etc.)
  • Nutrition/feed additives
  • Fragrances/flavors
  • Specialty chemicals (new materials)

Customers

  • Animal feed producers
  • Food & beverage companies
  • Pharma/nutraceutical companies

Where it sits in the supply chain

  • Health care/specialty chemicals
  • Vitamins & nutrition ingredients
  • Vitamin, carotenoid, fragrance…

What could go right

  • Global vitamin/feed-additive demand
  • Cost-driven share gains from Western producers

What could go wrong

  • Vitamin price cycles (oversupply-driven crashes)
  • Feed/livestock demand cyclicality

Moat: narrow (scale, cost advantage). Among the world's lowest-cost, largest-scale vitamin producers, squeezing higher-cost Western rivals.

Headquarters: Xinchang, Zhejiang, China · Founded: 1999 · Employees: 11,508

Named competitors

Zhejiang NHU at a glance

Size Zhejiang NHU (002001.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $11.8B, the 198th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥25.82 on 18 Nov 2026.

Performance Over six months the shares fell 21.6%, against +0.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 11 in its peer set.

Growth Revenue grew 10.6% over the last twelve months (peer median +9.1%); the operating margin is 33.3% (peer median 15.3%).

Valuation It trades at 9.7× forward earnings against a peer median of 21.0× (2nd cheapest of 8).

Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -25 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 16.8 points above its cost of capital (6.2% WACC).

Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 102002001.SZ 81
Six months, rebased to 100: Zhejiang NHU against the median of its 10 peers (local-currency closes).

Zhejiang NHU financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥24.8BCN¥22.1BCN¥21.5BCN¥15.1BCN¥15.9B
Revenue growth—+3%+43%-5%—
Gross profitCN¥12.5BCN¥9.58BCN¥8.69BCN¥4.73BCN¥5.66B
EBITDAn/aCN¥9.85BCN¥9.15BCN¥4.72BCN¥5.51B
Net incomeCN¥7.31BCN¥6.76BCN¥5.87BCN¥2.70BCN¥3.62B
Free cash flowCN¥6.07BCN¥6.98BCN¥5.51BCN¥737M-CN¥512M
Capital expenditureCN¥2.43BCN¥1.90BCN¥1.60BCN¥4.45BCN¥4.93B
Total debtCN¥7.61BCN¥8.10BCN¥9.12BCN¥9.98BCN¥10.4B

Quarterly statements and history in the cockpit →

Zhejiang NHU competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%+20%+40%CIPLAAUROPHARMALUPINABVX000423RVMD002603BHC002317000623002001.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang NHU is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×50×CIPLAAUROPHARMALUPIN000423002603BHC002317002001.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang NHU is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%CIPLAAUROPHARMALUPIN000423002603BHC002317000623002001.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang NHU is the large dot.

Zhejiang NHU competitors and peer comparison

Head to head with its named competitors (002001.SZ vs DSFIR.AS vs BAS.DE vs 600216.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang NHU 002001.SZ$11.8B-22%+11%33%9.7×-8.3%
DSM-Firmenich DSFIR.AS$27.5B+47%-45%8%28.6×23.7%
Basf BAS.DE$50.1B0%-4%7%15.8×5.7%
Zhejiang Medicine 600216.SS$1.51B-26%-6%7%11.5×-7.8%

How Zhejiang NHU compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang NHU against its 10 peers (data as of 18 Nov 2026)
Measure002001.SZPeer medianRank in peer set
1-month return-1.8%+0.8%4th lowest of 11
6-month return-21.6%+0.6%2nd lowest of 11
Distance from 52-week high-35.8%-22.1%2nd lowest of 11
Revenue growth (TTM)+10.6%+9.1%4th highest of 9
Operating margin33.3%15.3%highest of 10
Forward P/E9.7×21.0×2nd cheapest of 8
Growth the price implies (Req g, 7 yrs)-8.3%6.9%2nd least demanding of 9
Growth delivered (Del g)+16.7%+6.1%highest of 9
Hurdle (Req g minus delivered)-25.0 pp+1.2 ppleast demanding of 9
ROIC minus cost of capital+16.8 pp+2.5 pp2nd highest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang NHU 002001.SZChina$11.8B-22%+11%33%9.7×-8.3%+16.7%
Cipla CIPLA.NSIndia$12.2B+1%-1%13%29.1×28.4%+8.1%
Aurobindo Pharma AUROPHARMA.NSIndia$11.0B+19%+14%15%22.3×21.1%+6.3%
Lupin LUPIN.NSIndia$9.67B-14%+24%24%21.0×8.8%+13.0%
Abivax ABVX.PAFrance$7.36B-30%n/an/an/an/an/a
Dong-E-E-Jiao 000423.SZChina$4.99B+1%+8%29%17.8×-3.7%+14.5%
Revolution Medicines RVMDUnited States$34.6B+6%n/a-853%n/an/an/a
Shijiazhuang Yiling Pharmaceutical 002603.SZChina$3.83B-7%+32%21%17.5×-3.9%-2.2%
Bausch Health Companies BHC.TOCanada$3.27B+66%+10%27%2.0×-14.8%+5.9%
Guangdong Zhongsheng Pharmaceutical 002317.SZChina$3.00B+11%-14%9%91.7×33.8%+5.9%
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%n/a5.0%+1.0%

Questions

Who are Zhejiang NHU's main competitors?
Named competitors: DSM-Firmenich (DSFIR.AS), BASF (nutrition arm) (BAS.DE), Zhejiang Medicine (600216.SS). The cockpit's measured peer set (industry) also includes Cipla (CIPLA.NS), Aurobindo Pharma (AUROPHARMA.NS), Lupin (LUPIN.NS), Abivax (ABVX.PA), Dong-E-E-Jiao (000423.SZ), Revolution Medicines (RVMD).
Is Zhejiang NHU expensive compared with its peers?
On forward p/e it trades at 9.7× against a peer median of 21.0×, 2nd cheapest of 8 in its peer set. For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -25 pp: the price already allows for a slowdown.
How has Zhejiang NHU stock performed?
Over six months to 18 Nov 2026 the shares returned -21.6% against +0.6% for the median peer; over one year +6.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.